GSK Plc is pushing the UK government to give pharmaceutical companies more access to its public health data troves, to ...
Years after the biopharmaceutical industry stepped up to create COVID-19 vaccines as the virus spiraled into a global ...
For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...
Stock analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March ...
The U.S. Food and Drug Administration on Tuesday approved GSK's drug for a common type of urinary tract infection (UTI) in ...
GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...
NEW YORK, NY / ACCESS Newswire / March 27, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a ...
The drug is a needed new option for treating uncomplicated UTIs, a common infection that’s becoming harder to treat as rates ...
GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older: Philadelphia Friday, March 28, 202 ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
GSK PLC closed 18.56% short of its 52-week high of £18.24, which the company achieved on May 16th.
GSK Plc is studying a large group of elderly adults in the UK to determine if its blockbuster shingles vaccine reduces the risk of dementia, potentially opening the door to an expanded label for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results